Our top pick for
Arvinas, Inc is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Arvinas employs 133 staff and has a trailing 12-month revenue of around USD$46.9 million.
Since the stock market crash in March caused by coronavirus, Arvinas's share price has had significant negative movement.
Its last market close was USD$25.55, which is 49.38% down on its pre-crash value of USD$50.47 and 27.01% down on the lowest point reached during the March crash when the shares fell as low as USD$32.45.
If you had bought USD$1,000 worth of Arvinas shares at the start of February 2020, those shares would have been worth USD$703.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$511.51.
|Latest market close||USD$25.55|
|52-week range||USD$17 - USD$61.57|
|50-day moving average||USD$25.1338|
|200-day moving average||USD$34.7341|
|Wall St. target price||USD$60.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-7.159|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||10.56%|
|1 month (2020-10-26)||21.32%|
|3 months (2020-08-25)||0.47%|
|6 months (2020-05-22)||-41.98%|
|1 year (2019-11-25)||-25.96%|
|2 years (2018-11-23)||44.92%|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$46.9 million|
|Gross profit TTM||USD$43 million|
|Return on assets TTM||-19.32%|
|Return on equity TTM||-54.53%|
|Market capitalisation||USD$937.4 million|
TTM: trailing 12 months
There are currently 5.7 million Arvinas shares held short by investors – that's known as Arvinas's "short interest". This figure is 4.1% up from 5.4 million last month.
There are a few different ways that this level of interest in shorting Arvinas shares can be evaluated.
Arvinas's "short interest ratio" (SIR) is the quantity of Arvinas shares currently shorted divided by the average quantity of Arvinas shares traded daily (recently around 479477.09213863). Arvinas's SIR currently stands at 11.83. In other words for every 100,000 Arvinas shares traded daily on the market, roughly 11830 shares are currently held short.
However Arvinas's short interest can also be evaluated against the total number of Arvinas shares, or, against the total number of tradable Arvinas shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arvinas's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Arvinas shares in existence, roughly 140 shares are currently held short) or 0.1824% of the tradable shares (for every 100,000 tradable Arvinas shares, roughly 182 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arvinas.
Find out more about how you can short Arvinas stock.
We're not expecting Arvinas to pay a dividend over the next 12 months.
Over the last 12 months, Arvinas's shares have ranged in value from as little as $17 up to $61.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 1.4863. This would suggest that Arvinas's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.